Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — UBS 2021 Virtual Global Healthcare Conference
29 slides from Angiodynamics's conference presentation, May 25, 2021
Slide 1: The UBS 2021 Virtual Global Healthcare Conference
05 | 25 | 2021 ANGIODYNAMICS The UBS 2021 Virtual Global Healthcare Conference Jim Clemmer, President & CEO
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Strategic Transformation
PURSUE LARGER, FASTER GROWING MARKETSActive portfolio management enables us to compete in larger, faster growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment focused in areas that offer better opportunities for succ
Slide 4: Focused Transformation: U.S. Total Addressable Markets
4 FOCUSED TRANSFORMATIONU.S. Total Addressable Markets Began our strategic initiative to become a growth company 2018 Launch of the Auryon System gives us access to the peripheral atherectomy market New/Additional Thrombectomy & NanoKnife System portfolio additions & indications increase market acce
Slide 5: Product portfolio: invest for growth and maintain positioning
5 Diagnostic Catheters, Guidewires and Kits Vascular Access Catheters and Accessories Microwave & Radiofrequency Tumor Ablation Endovenous Laser Treatment Lung Biopsy Safety Radiation Treatment Stabilization Balloons INVEST FOR GROWTH MAINTAIN POSITIONING Thrombus Management Irreversible Electropora
Slide 6: Peripheral Atherectomy
PERIPHERAL ATHERECTOMY 6 05 | 25 | 2021
Slide 7: Auryon System
2.35 mmAspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mmAspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mmIndicated for Peripheral Atherectomy Why wavelength mattersEach type of tissue interacts differently
Slide 8: Peripheral Atherectomy US Addressable Markets & Competitive Landscape
PERIPHERAL ATHERECTOMYUS Addressable Markets & Competitive Landscape MECHANICAL LASER $555M 23%1 1. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millennium Research Group, Inc. 77%1 2020 Total Addressable Market (TAM) 8 Company Product Thrombus Plaque Fibrotic I
Slide 9: Peripheral Atherectomy: Continuing our momentum of growth
9 PERIPHERAL ATHERECTOMYContinuing our momentum of growth PRODUCT DEVELOPMENT Product development pipelinePortfolio and product indication expansionContinuous voice of customer CLINICAL COMPENDIUMExpand awareness by creating a strong podium and clinical publication presence Clinically differentiated
Slide 10: Thrombus Management
THROMBUS MANAGEMENT 10 05 | 25 | 2021
Slide 11: Deep Vein Thrombosis and Pulmonary Embolism
11 Deep Vein ThrombosisDVT + Pulmonary EmbolismPE = Venous ThromboembolismVTE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply DVT and PE are collectively referred to as VTE 208,
Slide 12: DVT & PE Treatment Options
12 DVT & PE TREATMENT OPTIONSPercutaneous Thrombectomy CDT & US-CDTCatheter-Directed Thrombolysis (with or without the assistance of ultrasound) PCMTPharmacomechanical Thrombectomy AngioVacContinuous Aspiration Suction Thrombectomy MTMechanical Retrieval Thrombectomy MAMechanical Aspiration(Small &
Slide 13: Purpose Built Portfolio & Technology
THROMBUS MANAGEMENTPurpose Built Portfolio & Technology 13 Right Atrium AngioVac’s use is currently focused on the Right Atrium, which is a $77M addressable market. Pulmonary Embolism Deep Vein Thrombosis AlphaVac, a multi-purpose mechanical aspiration device, will allow us to compete in the broader
Slide 14: The AngioVac System Difference
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous systemUtilizing a self-expanding, nitinol reinforced funnel tipSimultaneously reinfusing the patient’s own filtered blood to limit procedural blood lo
Slide 15: The Next Generation of AngioVac
THE NEXT GENERATION OF ANGIOVACPhysician requests for use in DVT drive new product development $1.6B Controlled Powerful Versatile THE NEXT PORTFOLIO INNOVATION A purpose-built, innovative product leveraging the strengths of the AngioVac cannula technology with off-circuit manual aspiration control
Slide 16: Addressable Market: Thrombus Procedures by Location
ADDRESSABLE MARKETThrombus Procedures by Location 16 Location in Body Avg. Diameter Size (mm) Compatible FR Size Acceptable Catheter Size (sans access) ANGO Product Pulmonary Embolism 19-28mm5 57-84 Fr 12-24 Fr AlphaVac C85 Right Atrium 44-53mm 132-159 Fr 18-24 Fr AngioVac C20/C180/C85 Inferior Vena
Slide 17: Planned Portfolio Additions & U.S. Addressable Markets Expansion
THROMBUS MANAGEMENTPlanned Portfolio Additions & U.S. Addressable Markets Expansion 17 $1.3B FY 2021 FY 2022 FY 2023 FY 2025 FY 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 $140M $700M $3.6B $1.5B 1 2 The planned portfolio additions are not guarantees of future performance and ar
Slide 18: Irreversible Electroporation
IRREVERSIBLE ELECTROPORATION 18 05 | 25 | 2021
Slide 19: Irreversible Electroporation: Non-thermal energy destroys cells
19 Probe placement Placement of probes around a target area provides effective treatment coverage a-d Electrical pulses cause pores to form within the cellular membrane leading to non-thermal cell death a-d Electrical field Decellularization Non-thermal Revascularization The NanoKnife System’s uniqu
Slide 20: Provides the Innovation Doctors Need
20 Localized Treatment Strong safety profile Maintains potential for future treatments Provides options for patients PROVIDES THE INNOVATION DOCTORS NEEDExpands treatment options and helps preserve patient's quality of life Spares critical structures and nerves Treated tissue can revascularize Prese
Slide 21: DIRECT Study and Prostate IDE
21 DIRECT StudyThis study is evaluating the use of the NanoKnife System as a potential treatment for stage III pancreatic cancer. Prostate IDEThis safety study will evaluate the use of the NanoKnife System as a focal therapy option for prostate tissue. Liver Oral Cavity Pancreas Kidney Bladder Melan
Slide 22: DIRECT Study: Data for IRE Cancer Treatment
22 DIRECT STUDYData for IRE Cancer Treatment Randomized Controlled Protocol Controlled Registry Protocol One Study Two Protocols High level of evidence and real-world evidence Overall Survival as primary endpoint Both have prospective control arms
Slide 23: Focal therapy and clinical expansion in prostate cancer
23 Focal therapy bridges the gap between whole gland treatment and active surveillance in an attempt to maximize quality of life by avoiding the effects of whole gland radiation or surgery.However…adoption remains low (<5%) due to gaps within existing technology. 27% would undergo radiotherapy of wh
Slide 24: Vascular Access
VASCULAR ACCESS 05 | 25 | 2021 24
Slide 25: Vascular Access: Safely delivering medication to patients
25 VASCULAR ACCESSSafely delivering medication to patients PORTFOLIO MARKET ACCESS PERFORMANCE PICCs Midlines Tip Location Ports Dialysis Point of Care Ultrasound Delivering on our product road map including development of an integrated navigation & tip location technology that enables the use of ou
Slide 26: Q3 YTD FY2021 Highlights
Q3 YTD FY2021 Highlights in millions (except per share data) YTD FY2021 YTD FY2020 YOY Change Revenue $214.2 $205.8 4.1% Gross Margin 53.4% 58.3% (490 bps) Net Loss ($12.1) ($9.7) ($2.4) GAAP EPS ($0.32) ($0.26) ($0.06) Adjusted EPS $0.05 $0.15 ($0.10) Adjusted EBITDA $15.0 $17.5 ($2.5) Financial Pe
Slide 27: | | 2021 ANGIODYNAMICS The UBS 2021 Virtual Global Healthcare ConferenceJim Clemmer, President &
05 | 25 | 2021 ANGIODYNAMICS The UBS 2021 Virtual Global Healthcare ConferenceJim Clemmer, President & CEO
Slide 28: Appendix A
Appendix A i>) angiodynamics
Slide 29: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees
AngioDynamics — UBS 2021 Virtual Global Healthcare Conference on 6ix